mAb could change treatment of hemophilia A, doc says

Breakthrough bleeds were successfully treated with standard episodic treatment, FVIII products, or bypassing agents.

Based on these results, Dr Nogami said emicizumab prophylaxis has the potential to change the treatment paradigm of hemophilia A, irrespective of inhibitor status.

*Hanabusa H et al, Updated results of an ongoing long-term phase 1/2 study of emicizumab (ACE910) in hemophilia A patients with or without inhibitors, WFH 2016 World Congress, July 2016.